A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy ; volume:7 ; number:3 ; day:16 ; month:3 ; year:2023 ; pages:405-416 ; date:5.2023
PharmacoEconomics - open ; 7, Heft 3 (16.3.2023), 405-416, 5.2023
- Creator
-
Cortesi, Paolo Angelo
Fornari, Carla
Gisondi, Paolo
Iannone, Florenzo
Antonazzo, Ippazio Cosimo
Aloisi, Elisabetta
Fiocchi, Martina
Ritrovato, Daniela
Mantovani, Lorenzo Giovanni
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-023-00404-3
- URN
-
urn:nbn:de:101:1-2023090708552596434231
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cortesi, Paolo Angelo
- Fornari, Carla
- Gisondi, Paolo
- Iannone, Florenzo
- Antonazzo, Ippazio Cosimo
- Aloisi, Elisabetta
- Fiocchi, Martina
- Ritrovato, Daniela
- Mantovani, Lorenzo Giovanni
- SpringerLink (Online service)
Other Objects (12)
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Secukinumab (nicht röntgenologische axiale Spondyloarthritis) : Nutzenbewertung gemäß § 35a SGB V
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Secukinumab (nicht röntgenologische axiale Spondyloarthritis) : Nutzenbewertung gemäß § 35a SGB V
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis
IL-17 producing mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A Review in Psoriatic Arthritis
Correction to: Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Correction to: Secukinumab: A Review in Psoriatic Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Secukinumab (nicht röntgenologische axiale Spondyloarthritis) : Nutzenbewertung gemäß § 35a SGB V
Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort
Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab
Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
A Review of the Use of Secukinumab for Psoriatic Arthritis